FGFR-4 Inhibitors via Covalent Warhead Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by FGFR-4, such as cancers, face challenges in selectively inhibiting FGFR-4 without affecting other FGFR isoforms, leading to potential toxicities and limited efficacy due to the lack of specific inhibitors.
Innovation Solution
Development of compounds with a warhead moiety capable of forming a covalent bond with FGFR-4, specifically targeting and inhibiting the FGFR-4 protein by forming a covalent bond with a cysteine residue, thereby providing selective inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective FGFR inhibitors are used to treat conditions mediated by FGFR-4, then FGFR-4 activity is inhibited, but other FGFR isoforms are also inhibited leading to toxicities
Solution Approach 1:
The patent applies local quality by introducing a warhead moiety that specifically targets and forms a covalent bond with a cysteine residue present only in FGFR-4, while other FGFR isoforms lack this specific cysteine residue. This localized chemical modification at the specific cysteine site enables selective inhibition of FGFR-4 without affecting other FGFR isoforms, thereby achieving high selectivity while avoiding off-target toxicities
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure to include a warhead moiety with specific reactivity parameters that enable covalent bonding to the cysteine residue. The warhead moiety contains electrophilic atoms with specific leaving groups that change the chemical reactivity profile of the inhibitor, allowing it to form irreversible covalent bonds with FGFR-4's cysteine residue while maintaining selectivity against other FGFR isoforms
2Reliability
If FGFR-4 inhibitors are developed to treat cancers, then therapeutic efficacy is improved, but selective inhibition without affecting other FGFR isoforms is challenging
Solution Approach 1:
The patent resolves the complexity of achieving selective inhibition by focusing on a local distinguishing feature - the presence of a specific cysteine residue in FGFR-4 that is absent in other FGFR isoforms. The warhead moiety is designed to specifically target this local feature, simplifying the path to selectivity without requiring complex structural modifications throughout the entire molecule
Solution Approach 2:
The warhead moiety acts as an intermediary that mediates between the inhibitor core and the FGFR-4 target. This intermediary component provides the selective covalent bonding capability while allowing the rest of the inhibitor structure to maintain affinity for the FGFR binding site, thereby simplifying the overall design by separating the selectivity function from the binding function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit FGFR-4 activity, offering a potential therapeutic approach for conditions like hepatocellular carcinoma, breast cancer, ovarian cancer, and others by selectively targeting FGFR-4 without affecting other FGFR isoforms, thus minimizing toxicities.
Implementation Method 1
compounds with a warhead moiety capable of forming a covalent bond with FGFR-4, specifically targeting and inhibiting the FGFR-4 protein by forming a covalent bond with a cysteine residue
Data Source
AI summary
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.